In conclusion, our study suggests that vitamin C expands the therapeutic window of PI3K inhibitor buparlisib in treating PIK3CA-mutated TNBC by promoting KDM5-mediated H3K4 demethylation to suppress the expression of PI3K pathway genes and other genes relevant to cancer growth and metastasis. The gene discussed is PIK3CA; the disease is cancer.